Transforming growth factor beta receptor complex (TGF-beta/TGFBR complex)

The Transforming growth factor beta (TGF-beta) signaling complex is a pivotal regulatory unit comprising TGF-beta ligands (TGF-beta 1, 2, and 3) and their cognate type I and type II serine/threonine kinase receptors (TGFBR1 and TGFBR2), often modulated by co-receptors like endoglin or betaglycan (UniProt P01137, P36897). This complex initiates a signaling cascade, primarily through SMAD proteins, that governs essential cellular processes such as growth, differentiation, and immune homeostasis (PubMed 28115566). In the context of disease, particularly oncology, the TGF-beta interface acts as a "double-edged sword," functioning as a tumor suppressor in early stages but promoting metastasis and immune evasion in advanced cancers (PubMed 30635454). Therapeutic interventions targeting this interface include monoclonal antibodies that sequester the ligand, small molecule inhibitors of the TGFBR1 kinase domain, and bifunctional fusion proteins designed to block both TGF-beta and immune checkpoints (NIH ClinicalTrials.gov). However, the broad physiological roles of TGF-beta present significant safety challenges, including potential cardiotoxicity and the development of secondary skin lesions, necessitating careful patient selection and dosing strategies (StatPearls).

Other names

TGF-beta signaling complexTGFB-TGFBR interfaceTGF-beta signaling axisTransforming growth factor beta and TGFβ–receptor / cofactor interfaces

Inhibition of ligand-receptor binding through neutralizing antibodies or decoy receptors, and inhibition of intracellular signaling via small molecule kinase inhibitors targeting the TGF-beta type I receptor.